

# **Notes on Top Regimens by Diagnostic Group report**

### Introduction

The Top Regimens by Diagnostic Group report provides an overview of the most frequently administered regimens for the major tumour groups.

For this report the range of analyses has been expanded, following advice from a series of clinical workshops. There are now analyses of selected individual tumour sites. The large volume sites of breast and colorectal cancers have also been split to show curative and palliative treatment. This analysis of treatment intent is dependent on trusts supplying the appropriate data field; currently only 71% of records submitted contain this item.

Within the report, there may be some records present where the diagnosis does not match the treatment recorded. This report reflects how data has been submitted to CIU.

This report excludes activity for patients under the age of 16 at the time of starting a regimen. Activity is included if it occurs between January 2014 and December 2014. Oral chemotherapy may be under-represented, particularly for haematological groups.

#### **Definition of Terms**

The following terms are used in this report:

#### All submitting trusts aggregated

The total aggregated activity for all NHS hospital trusts that have submitted data at the time the report was produced.

#### **Number of Patients**

The number of unique patients with a primary diagnosis recorded that matches the relevant diagnostic group. Unique patients are identified by NHS number, date of birth and gender. The total number of patients receiving a regimen is indicated in parenthesis beside the regimen name.

A patient that receives chemotherapy treatment for multiple diagnoses in different diagnostic groupings and within the reporting period specified will be counted more than once.

#### Number of First Cycles

The number of patients with a primary diagnosis matching the relevant diagnostic group that have started a cycle of chemotherapy with a recognised regimen grouping within the reporting period. Patients starting multiple different regimens will be counted once in each regimen group.


#### Total Cycles

The aggregate total number of cycles delivered of the specified regimen to all patients with a primary diagnosis matching the relevant diagnostic group. This includes first cycles.



# **Number of Patients by Diagnostic Group**

All submitting trusts aggregated





# **Number of Patients by Diagnostic Group**

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over

**Table: Patients by Diagnostic Group** 


	Number of patients
Primary Diagnosis	All submitting trusts aggregated
Brain/CNS	2,707
Breast	30,918
Gynae	11,447
Head and Neck	3,092
Leukaemia	6,665
Lower GI	20,884
Lung	18,216
Lymphoma	15,567
Myeloma	7,411
Other	9,292
Sarcoma	1,777
Skin	2,095
Upper GI	12,837
Urology	14,661



# Brain/CNS

ICD10: C47, C69-C72

### All submitting trusts aggregated





# Brain/CNS

ICD10: C47, C69-C72

### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
TEMOZOLOMIDE	1,467	1,180	4,922
PCV	574	469	1,527
TEMOZOLOMIDE + RT	594	550	1,164
BEVACIZUMAB	84	49	581
TRIAL	77	64	346
LOMUSTINE	147	128	290
HYDROXYCARBAMIDE	112	19	203
CARBOPLATIN + ETOPOSIDE	36	33	93
VINBLASTINE	4	3	63
CARBOPLATIN	25	24	53
Other (136 regimens, including 2 other TRIAL regimen and 49 unrecognised)	389	323	1,194



Breast - Curative (curative, adjuvant and neo-adjuvant) ICD10: C50

#### All submitting trusts aggregated





Breast - Curative (curative, adjuvant and neo-adjuvant)

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
TRASTUZUMAB	4,614	3,090	28,511
FEC	6,523	5,658	22,427
FEC + DOCETAXEL	2,528	1,984	9,725
DOCETAXEL	3,377	2,894	8,804
PACLITAXEL	952	866	4,595
EC	1,390	1,217	4,356
CYCLOPHOSPHAMIDE + DOCETAXEL	472	413	1,615
DOCETAXEL + TRASTUZUMAB	414	366	1,217
FEC + DOCETAXEL + TRASTUZUMAB	183	124	905
TCH	161	101	828
Other (303 regimens, including 9 other TRIAL regimen and 194 unrecognised)	2,856	2,344	10,723



**Breast - Palliative** 

ICD10: C50

#### All submitting trusts aggregated





Breast - Palliative

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
TRASTUZUMAB	1,538	863	12,050
CAPECITABINE	1,915	1,473	9,856
PACLITAXEL	1,303	1,079	7,881
DENOSUMAB	1,108	747	5,930
ERIBULIN	612	485	2,756
TRASTUZUMAB EMTANSINE	430	410	2,325
DOCETAXEL	574	462	2,143
VINORELBINE	521	437	2,035
EVEROLIMUS	432	338	1,783
DOCETAXEL + PERTUZUMAB + TRASTUZUMAB	296	258	1,580
Other (265 regimens, including 10 other TRIAL regimen and 151 unrecognised)	2,866	2,228	13,377





Breast (All)

#### All submitting trusts aggregated





Breast (All)

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
TRASTUZUMAB	8,707	5,432	57,216
FEC	8,141	7,024	27,822
PACLITAXEL	2,835	2,407	15,235
DOCETAXEL	4,681	3,983	12,874
FEC + DOCETAXEL	3,358	2,681	12,840
CAPECITABINE	2,475	1,855	12,041
DENOSUMAB	2,373	1,512	11,395
EC	2,146	1,824	6,900
ERIBULIN	823	639	3,643
TRASTUZUMAB EMTANSINE	598	573	3,136
Other (615 regimens, including 19 other TRIAL regimen and 421 unrecognised)	10,208	8,161	42,557



Gynae (All Gynae)

#### All submitting trusts aggregated





Gynae (All Gynae)
ICD10: C51-C58

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CARBOPLATIN + PACLITAXEL	4,264	3,394	16,409
CARBOPLATIN	2,705	2,176	9,276
BEVACIZUMAB	1,036	703	6,113
PACLITAXEL	834	684	4,029
GEMCARBO	720	584	2,823
LIPOSOMAL DOXORUBICIN	755	618	2,050
CARBOPLATIN + LIPOSOMAL DOX	514	386	1,828
CISPLATIN + RT	507	466	1,800
CISPLATIN	379	351	1,329
BEVACIZUMAB + CARBO + GEMCITABINE	268	214	1,294
Other (377 regimens, including 16 other TRIAL regimen and 207 unrecognised)	2,656	2,231	9,285



Gynae (Cervix)

### All submitting trusts aggregated





Gynae (Cervix)

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CISPLATIN + RT	431	397	1,543
CISPLATIN	273	258	1,001
CARBOPLATIN + PACLITAXEL	276	232	990
CARBOPLATIN	73	63	212
BEVACIZUMAB + CARBO + PACLITAXEL	50	50	167
PACLITAXEL	30	23	135
TRIAL	21	21	118
BEVACIZUMAB	32	30	101
CISPLATIN + TOPOTECAN	27	17	82
CARBOPLATIN + ETOPOSIDE	20	14	63
Other (74 regimens, including 3 other TRIAL regimen and 32 unrecognised)	167	147	551



Gynae (Endometrium)

### All submitting trusts aggregated





Gynae (Endometrium)

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CARBOPLATIN + PACLITAXEL	906	736	3,421
CARBOPLATIN	272	222	927
PACLITAXEL	49	42	196
LIPOSOMAL DOXORUBICIN	51	47	133
CARBOPLATIN + LIPOSOMAL DOX	36	31	118
CISPLATIN + DOXORUBICIN	32	23	118
TRIAL	23	20	96
DOXORUBICIN	20	18	67
GEMCARBO	18	13	55
CARBOPLATIN + DOXORUBICIN	12	10	49
Other (91 regimens, including 5 other TRIAL regimen and 35 unrecognised)	190	165	600



Gynae (Ovarian) ICD10: C56, C570

### All submitting trusts aggregated





Gynae (Ovarian) ICD10: C56, C570

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
CARBOPLATIN + PACLITAXEL	2,727	2,137	10,810
CARBOPLATIN	2,242	1,795	7,752
BEVACIZUMAB	981	659	5,901
PACLITAXEL	709	582	3,483
GEMCARBO	673	547	2,648
LIPOSOMAL DOXORUBICIN	674	546	1,832
CARBOPLATIN + LIPOSOMAL DOX	458	341	1,653
BEVACIZUMAB + CARBO + GEMCITABINE	265	212	1,284
BEVACIZUMAB + CARBO + PACLITAXEL	232	196	1,038
TRIAL	169	137	754
Other (269 regimens, including 9 other TRIAL regimen and 146 unrecognised)	1,472	1,220	4,826



# Head and Neck

ICD10: C00-C14, C30-C32

### All submitting trusts aggregated





# Head and Neck

ICD10: C00-C14, C30-C32

### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CISPLATIN + RT	1,059	997	2,789
CISPLATIN	561	518	1,764
CISPLATIN + FLUOROURACIL	386	337	957
CETUXIMAB	177	153	754
CISPLATIN + DOCETAXEL + FLUOROURACIL	283	263	751
CETUXIMAB + RT	170	157	734
CARBOPLATIN	190	177	393
TRIAL	72	57	366
CARBO + FLUOROURACIL	117	103	340
CETUXIMAB + CISPLATIN + FU	59	50	178
Other (139 regimens, including 2 other TRIAL regimen and 66 unrecognised)	689	621	1,821



# Leukaemia (All Leukaemia) ICD10: C91-C95, C962, C964, C968

### All submitting trusts aggregated





Leukaemia (All Leukaemia) ICD10: C91-C95, C962, C964, C968

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
IMATINIB	1,147	544	4,289
AZACITIDINE	348	239	2,407
NILOTINIB	426	243	1,722
FCR	482	375	1,659
BENDAMUSTINE + RITUXIMAB	488	399	1,598
AML17	353	329	919
TRIAL	185	140	878
DASATINIB	209	100	805
CHLORAMBUCIL	268	205	707
RITUXIMAB	261	211	658
Other (569 regimens, including 10 other TRIAL regimen and 401 unrecognised)	3,978	3,336	9,710



# Leukaemia (ALL) ICD10: C910, C915, C918

### All submitting trusts aggregated





Leukaemia (ALL) ICD10: C910, C915, C918

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
UKALL2014	169	135	590
UKALL2003	57	13	292
METHOTREXATE INTRATHECAL	109	66	288
UKALL2011	71	52	240
DASATINIB	22	14	116
IMATINIB	30	22	102
VINCRISTINE	29	26	85
METHOTREXATE	32	13	76
UKALL XII	19	11	68
UKALL60+	24	20	58
Other (167 regimens, including 3 other TRIAL regimen and 105 unrecognised)	351	306	683



Leukaemia (AML)
ICD10: C920, C923-C926, C928, C93, C940, C942-C944, C962, C964, C968

### All submitting trusts aggregated





Leukaemia (AML) ICD10: C920, C923-C926, C928, C93, C940, C942-C944, C962, C964, C968

### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
AZACITIDINE	279	197	1,994
AML17	335	315	889
DA	320	308	480
CYTARABINE	166	140	359
TRIAL	61	53	198
FLAG + IDARUBICIN	137	130	197
HYDROXYCARBAMIDE	85	75	135
CYTARABINE HIGH DOSE	84	78	119
FLAG	33	29	69
RITUXIMAB	30	26	52
Other (214 regimens, including 3 other TRIAL regimen and 129 unrecognised)	710	630	1,363



Leukaemia (CLL)

#### All submitting trusts aggregated





Leukaemia (CLL)

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
FCR	456	354	1,576
BENDAMUSTINE + RITUXIMAB	468	381	1,539
CHLORAMBUCIL	259	197	672
IBRUTINIB	181	181	610
TRIAL	98	65	584
RITUXIMAB	194	152	510
BENDAMUSTINE	112	79	326
RIALTO TRIAL	57	41	244
ALEMTUZUMAB	44	34	236
CHLORAMBUCIL + RITUXIMAB	93	84	232
Other (187 regimens, including 2 other TRIAL regimen and 130 unrecognised)	554	452	1,420



# Leukaemia (CML)

ICD10: C921

#### All submitting trusts aggregated





Leukaemia (CML)

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
IMATINIB	1,056	485	4,019
NILOTINIB	389	219	1,607
DASATINIB	175	78	658
SPIRIT TRIAL	39	7	185
BOSUTINIB	29	18	102
AZACITIDINE	13	7	85
HYDROXYCARBAMIDE	62	48	78
SPIRIT2 TRIAL	7	0	38
DA	14	13	15
PONATINIB	5	5	15
CYTARABINE	4	4	15
MERCAPTOPURINE	1	1	15
Other (55 regimens, including 1 other TRIAL regimen and 27 unrecognised)	108	100	215






Lower GI (Anal)

ICD10: C21

#### All submitting trusts aggregated





Lower GI (Anal)

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
FLUOROURACIL + MITOMYCIN + RT	217	212	253
FLUOROURACIL + MITOMYCIN	196	187	238
CISPLATIN + FLUOROURACIL	59	47	211
CAPECITABINE	21	17	71
CAPECITABINE + MITOMYCIN	55	54	58
FLUOROURACIL	50	49	50
OXALIPLATIN + MDG	10	7	47
CAPECITABINE + CISPLATIN	12	10	34
CAPECITABINE + OXALIPLATIN	8	8	34
CAPECITABINE + RT	25	25	29
Other (56 regimens, including 2 other TRIAL regimen and 24 unrecognised)	166	144	349



Lower GI (Colorectal) - Curative (curative, adjuvant and neo-adjuvant)

#### All submitting trusts aggregated





Lower GI (Colorectal) - Curative (curative, adjuvant and neo-adjuvant)

#### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CAPECITABINE + OXALIPLATIN	2,502	2,061	10,876
OXALIPLATIN + MDG	1,721	1,359	10,349
CAPECITABINE	2,049	1,776	6,926
FLUOROURACIL	679	528	6,078
IRINOTECAN + MDG	183	138	976
CAPECITABINE + RT	750	738	956
BEVACIZUMAB	60	42	391
CETUXIMAB	71	60	348
BEVACIZUMAB + IRINOTECAN + MdG	43	35	256
BEVACIZUMAB + OXALIPLATIN + MdG	51	40	255
Other (149 regimens, including 8 other TRIAL regimen and 76 unrecognised)	799	602	3,003



Lower GI (Colorectal) - Palliative

#### All submitting trusts aggregated





Lower GI (Colorectal) - Palliative

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
IRINOTECAN + MDG	1,523	1,208	8,577
OXALIPLATIN + MDG	1,299	1,071	7,235
CAPECITABINE + OXALIPLATIN	1,249	1,037	4,792
BEVACIZUMAB	636	459	4,000
CETUXIMAB	563	442	3,981
CAPECITABINE	860	711	3,086
BEVACIZUMAB + CAPE + OXALIPLATIN	567	459	2,493
AFLIBERCEPT + FU + IRINOTECAN	409	336	2,409
CETUXIMAB + IRINOTECAN + MDG	359	278	2,224
BEVACIZUMAB + OXALIPLATIN + MDG	342	290	2,013
Other (203 regimens, including 4 other TRIAL regimen and 116 unrecognised)	2,698	2,146	13,301



Lower GI (Colorectal) - All ICD10: C18-C20

#### All submitting trusts aggregated





Lower GI (Colorectal) - All ICD10: C18-C20

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
OXALIPLATIN + MDG	4,217	3,315	24,458
CAPECITABINE + OXALIPLATIN	4,856	3,984	20,060
CAPECITABINE	3,757	3,173	12,723
IRINOTECAN + MDG	2,241	1,731	12,343
FLUOROURACIL	1,310	1,031	10,315
BEVACIZUMAB	1,041	752	6,232
CETUXIMAB	877	664	5,967
BEVACIZUMAB + CAPE + OXALIPLATIN	842	641	3,709
AFLIBERCEPT + FU + IRINOTECAN	574	464	3,341
CETUXIMAB + IRINOTECAN + MDG	542	423	3,261
Other (371 regimens, including 10 other TRIAL regimen and 223 unrecognised)	5,705	4,658	22,252



Lung (all excluding Mesothelioma) ICD10: C33-C34, C37-C39

#### All submitting trusts aggregated





Lung (all excluding Mesothelioma) ICD10: C33-C34, C37-C39

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CARBOPLATIN + ETOPOSIDE	3,130	2,665	9,836
GEMCARBO	2,424	2,129	6,959
CARBOPLATIN + PEMETREXED	1,978	1,738	5,592
ERLOTINIB	1,341	956	4,997
CISPLATIN + PEMETREXED	1,775	1,596	4,863
PEMETREXED	956	771	4,065
CISPLATIN + VINORELBINE	1,263	1,144	3,421
CARBOPLATIN + VINORELBINE	1,221	1,110	3,386
GEFITINIB	451	255	2,533
DOCETAXEL	824	733	2,183
Other (311 regimens, including 12 other TRIAL regimen and 182 unrecognised)	3,843	3,346	10,618



Lung (Mesothelioma)
ICD10: C45; Morphology: M9050/3, M9052/0, M9052/3, M9053/3

#### All submitting trusts aggregated





Lung (Mesothelioma)
ICD10: C45; Morphology: M9050/3, M9052/0, M9052/3, M9053/3

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CARBOPLATIN + PEMETREXED	749	637	2,393
CISPLATIN + PEMETREXED	443	395	1,356
VINORELBINE	132	125	431
TRIAL	78	71	340
GEMCARBO	30	26	101
PEMETREXED	36	33	87
IPM	35	27	85
CARBOPLATIN	12	11	38
CISPLATIN	10	7	29
CARBOPLATIN + VINORELBINE	10	10	24
Other (42 regimens, including 27 unrecognised)	90	84	212



Lung (NSCLC)
ICD10: C33-C34, C37-C39; Morphology: M8012/3, M8013/3, M8046/3, M8070/3, M8070/6, M8075/3, M8140/3, M8140/6, M8246/3, M8250/3, M8255/3, M8310/3, M8560/3

#### All submitting trusts aggregated





Lung (NSCLC)
ICD10: C33-C34, C37-C39; Morphology: M8012/3, M8013/3, M8046/3, M8070/3, M8070/6, M8075/3, M8140/3, M8140/6, M8246/3, M8250/3, M8255/3, M8310/3, M8560/3

#### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
GEMCARBO	1,120	977	3,232
CARBOPLATIN + PEMETREXED	1,023	923	2,943
ERLOTINIB	739	527	2,920
CISPLATIN + PEMETREXED	866	775	2,348
CISPLATIN + VINORELBINE	714	644	2,016
CARBOPLATIN + VINORELBINE	734	673	2,005
PEMETREXED	449	351	1,993
GEFITINIB	246	128	1,492
DOCETAXEL	382	336	1,011
DENOSUMAB	150	132	527
Other (161 regimens, including 11 other TRIAL regimen and 104 unrecognised)	1,190	1,047	3,125



Lung (SCLC)
ICD10: C33-C34, C37-C39; Morphology: M8002/3, M8041/3

#### All submitting trusts aggregated





Lung (SCLC)
ICD10: C33-C34, C37-C39; Morphology: M8002/3, M8041/3

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
CARBOPLATIN + ETOPOSIDE	1,483	1,264	4,641
CISPLATIN + ETOPOSIDE	214	193	624
CAV	108	96	306
CARBOPLATIN	127	115	280
TOPOTECAN	72	69	139
STOMP TRIAL	26	26	90
EP	26	17	61
TRIAL	11	7	37
DENOSUMAB	14	13	24
GEMCARBO	11	10	20
IPILIMUMAB	8	2	20
Other (44 regimens, including 1 other TRIAL regimen and 19 unrecognised)	96	91	195





Lymphoma (All Lymphoma)
ICD10: C81-C86, C88, C913-C914, C916-C917, C919 or various morphology codes

#### All submitting trusts aggregated





Lymphoma (All Lymphoma)
ICD10: C81-C86, C88, C913-C914, C916-C917, C919 or various morphology codes

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	<b>Total Cycles</b>
CHOP R	4,135	3,420	15,580
RITUXIMAB	3,783	2,244	12,129
ABVD	1,203	966	5,166
CVP R	1,302	1,002	5,094
BENDAMUSTINE + RITUXIMAB	1,119	919	4,107
CHOP	511	423	1,668
BENDAMUSTINE	217	176	817
TRIAL	204	138	763
BRENTUXIMAB	197	163	737
REMODL TRIAL	167	139	671
Other (747 regimens, including 14 other TRIAL regimen and 482 unrecognised)	6,476	5,552	16,645



# Lymphoma (Hodgkin lymphoma) ICD10: C81 or various morphology codes

#### All submitting trusts aggregated





# Lymphoma (Hodgkin lymphoma) ICD10: C81 or various morphology codes

#### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
ABVD	1,175	944	5,052
BRENTUXIMAB	132	107	542
CHLVPP	98	82	285
CHOP R	62	54	246
TRIAL	52	42	196
RITUXIMAB	64	43	189
BEACOPP	38	34	180
CVP R	33	29	125
ESHAP	46	44	110
VEPEMB	29	24	101
Other (166 regimens, including 3 other TRIAL regimen and 58 unrecognised)	577	505	1,416



Lymphoma (NHL aggressive)
ICD10: C824, C831, C833, C835, C837, C846-C847, C852 or various morphology codes

#### All submitting trusts aggregated





Lymphoma (NHL aggressive)
ICD10: C824, C831, C833, C835, C837, C846-C847, C852 or various morphology codes

#### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
CHOP R	1,567	1,300	6,114
RITUXIMAB	436	331	1,154
REMODL TRIAL	128	103	523
METHOTREXATE INTRATHECAL	131	114	368
CVP R	101	87	298
CHOP	98	79	286
BENDAMUSTINE + RITUXIMAB	75	62	260
RCEOP	56	47	255
R GCVP	31	27	121
R CODOX M	27	23	111
Other (235 regimens, including 5 other TRIAL regimen and 106 unrecognised)	1,373	1,212	3,254



Lymphoma (NHL indolent)
ICD10: C82, C830, C880, C884, C913-C914, C916-C917, C919 or various morphology codes

#### All submitting trusts aggregated





Lymphoma (NHL indolent)
ICD10: C82, C830, C880, C884, C913-C914, C916-C917, C919 or various morphology codes

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	<b>Total Cycles</b>
RITUXIMAB	1,508	843	5,085
CVP R	441	327	1,881
BENDAMUSTINE + RITUXIMAB	420	352	1,554
CHOP R	305	244	1,188
BENDAMUSTINE	86	66	355
GALLIUM TRIAL	53	10	263
TRIAL	51	29	226
CHLORAMBUCIL	69	51	221
CLADRIBINE	103	99	186
CHLORAMBUCIL + RITUXIMAB	49	38	181
Other (214 regimens, including 7 other TRIAL regimen and 108 unrecognised)	964	780	2,623



# Myeloma ICD10: C90, D472, E85

#### All submitting trusts aggregated





Myeloma ICD10: C90, D472, E85

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
CVD	2,862	2,316	12,252
LENALIDOMIDE	1,655	973	8,626
CTD	901	706	2,806
MYELOMA XI TRIAL	496	372	2,336
POMALIDOMIDE	282	239	1,067
MELPHALAN	684	637	941
TRIAL	174	128	940
CYCLOPHOSPHAMIDE	298	265	638
VMP	162	134	629
CYCLOPHOSPHAMIDE + LENALIDOMIDE	179	137	607
Other (361 regimens, including 9 other TRIAL regimen and 284 unrecognised)	1,706	1,444	4,308



#### Sarcoma

ICD10: C40-C41, C46, C49 or various morphology codes

#### All submitting trusts aggregated





### Sarcoma

ICD10: C40-C41, C46, C49 or various morphology codes

#### All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
IMATINIB	438	226	2,292
DOXORUBICIN	261	237	772
TRABECTEDIN	124	93	509
DOCETAXEL + GEMCITABINE	127	114	404
LIPOSOMAL DOXORUBICIN	99	73	335
MIFAMURTIDE	29	27	279
PACLITAXEL	59	49	260
SUNITINIB	57	40	241
TRIAL	51	37	215
DOXORUBICIN + IFOSFAMIDE	61	52	200
Other (193 regimens, including 5 other TRIAL regimen and 75 unrecognised)	1,053	863	3,438



# Sarcoma (Bone) ICD10: C40-C41 or various morphology codes

#### All submitting trusts aggregated





Sarcoma (Bone)
ICD10: C40-C41 or various morphology codes

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
MIFAMURTIDE	23	21	218
CISPLATIN + DOXORUBICIN	43	36	129
ETOPOSIDE + IFOSFAMIDE	38	34	127
MAP	25	17	102
EURO-EWING	18	9	102
DOXORUBICIN	28	26	68
DOCETAXEL + GEMCITABINE	18	15	68
DOXORUBICIN + HD MTX	20	13	54
METHOTREXATE HIGH DOSE	9	8	54
TRIAL	10	9	45
Other (72 regimens, including 1 other TRIAL regimen and 20 unrecognised)	185	162	560



Sarcoma (GIST)
Morphology: M8936

### All submitting trusts aggregated





Sarcoma (GIST) Morphology: M8936

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
IMATINIB	336	147	1,725
SUNITINIB	40	24	164
REGORAFENIB	26	15	103
CARBOPLATIN	9	1	54
BEVACIZUMAB	2	1	23
OXALIPLATIN + MDG	2	2	22
TRIAL	8	6	21
CAPECITABINE + OXALIPLATIN	1	0	7
CAPECITABINE	3	2	6
CARBOPLATIN + PACLITAXEL	1	1	6
CHOP R	1	1	6
Other (16 regimens, including 4 unrecognised)	28	18	65



# Sarcoma (Soft tissue) ICD10: C49 or various morphology codes

#### All submitting trusts aggregated





Sarcoma (Soft tissue)
ICD10: C49 or various morphology codes

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
DOXORUBICIN	229	207	692
IMATINIB	98	76	547
TRABECTEDIN	123	92	508
DOCETAXEL + GEMCITABINE	109	99	336
DOXORUBICIN + IFOSFAMIDE	58	49	191
IFOSFAMIDE	56	47	178
PAZOPANIB	66	57	175
PACLITAXEL	37	31	157
TRIAL	33	22	149
LIPOSOMAL DOXORUBICIN	47	36	145
Other (144 regimens, including 4 other TRIAL regimen and 56 unrecognised)	515	438	1,725



### Skin

ICD10: C43-C44 or various morphology codes

#### All submitting trusts aggregated





Skin

ICD10: C43-C44 or various morphology codes

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
VEMURAFENIB	504	384	1,978
IPILIMUMAB	651	619	1,684
TRIAL	204	121	1,097
DACARBAZINE	373	338	952
VISMODEGIB	75	57	367
DABRAFENIB	73	73	230
PAZOPANIB	50	43	200
AXITINIB	31	26	116
SUNITINIB	24	14	91
CARBOPLATIN + ETOPOSIDE	24	21	86
Other (147 regimens, including 7 other TRIAL regimen and 48 unrecognised)	617	529	1,702



# Skin (Melanoma) ICD10: C43 or various morphology codes

#### All submitting trusts aggregated





Skin (Melanoma)
ICD10: C43 or various morphology codes

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
VEMURAFENIB	492	375	1,935
IPILIMUMAB	615	583	1,589
TRIAL	193	111	1,060
DACARBAZINE	363	328	938
DABRAFENIB	71	71	227
BLEOMYCIN	49	43	59
TEMOZOLOMIDE	26	25	58
INTERFERON	14	9	51
PEMBROLIZUMAB	18	18	47
DENOSUMAB	23	23	40
CARBOPLATIN	14	12	40
Other (86 regimens, including 4 other TRIAL regimen and 33 unrecognised)	226	190	636





Skin (Other) ICD10: C44

### All submitting trusts aggregated





Skin (Other) ICD10: C44

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
VISMODEGIB	74	56	366
PAZOPANIB	48	41	196
AXITINIB	31	26	116
IPILIMUMAB	36	36	95
SUNITINIB	24	14	91
CARBOPLATIN + ETOPOSIDE	22	19	79
ABIRATERONE	7	5	48
VEMURAFENIB	12	9	43
TRIAL	11	10	37
TEMSIROLIMUS	2	1	34
Other (96 regimens, including 4 other TRIAL regimen and 17 unrecognised)	255	220	718



Upper GI (All Upper GI)
ICD10: C15-C17, C22-C25

### All submitting trusts aggregated





Upper GI (All Upper GI)
ICD10: C15-C17, C22-C25

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
GEMCITABINE	1,839	1,502	6,421
EOX	1,928	1,642	6,168
ECX	2,076	1,778	5,754
CISPLATIN + GEMCITABINE	851	691	3,546
FLUOROURACIL + IRINOTECAN + OXALIPLATIN	559	468	2,852
OXALIPLATIN + MDG	358	290	1,737
CAPECITABINE + GEMCITABINE	416	287	1,528
CAPECITABINE + CISPLATIN	552	502	1,348
IMATINIB	250	106	1,299
TRASTUZUMAB	205	151	1,095
Other (375 regimens, including 15 other TRIAL regimen and 204 unrecognised)	5,791	4,961	17,765





Upper GI (Oesophago-gastric)

### All submitting trusts aggregated





Upper GI (Oesophago-gastric)
ICD10: C15-C16

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
EOX	1,889	1,609	6,043
ECX	2,050	1,755	5,665
CAPECITABINE + CISPLATIN	547	497	1,335
TRASTUZUMAB	202	150	1,085
DOCETAXEL	341	311	944
HCX	199	152	797
CISPLATIN + FLUOROURACIL	314	289	644
PACLITAXEL	152	130	627
IMATINIB	106	51	535
CAPECITABINE + CARBOPLATIN	196	176	528
Other (224 regimens, including 9 other TRIAL regimen and 105 unrecognised)	2,242	1,957	6,323



Upper GI (Pancreas)

ICD10: C25

### All submitting trusts aggregated





Upper GI (Pancreas)

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over


Regimen	Total Patients	First Cycles	Total Cycles
GEMCITABINE	1,569	1,276	5,473
FLUOROURACIL + IRINOTECAN + OXALIPLATIN	547	456	2,809
CAPECITABINE + GEMCITABINE	401	278	1,475
GEMCITABINE + NAB PACLITAXEL	217	216	676
OXALIPLATIN + MDG	125	104	536
IRINOTECAN + MDG	69	52	382
TRIAL	96	76	371
CISPLATIN + GEMCITABINE	83	67	358
CAPECITABINE	103	86	267
ESPAC TRIAL	59	39	267
Other (127 regimens, including 2 other TRIAL regimen and 66 unrecognised)	757	616	2,499





Urology (Bladder)

### All submitting trusts aggregated





Urology (Bladder)

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
BCG	753	483	2,947
CISPLATIN + GEMCITABINE	1,004	858	2,938
GEMCARBO	649	547	2,017
MITOMYCIN INTRAVESICULAR	378	348	1,034
TRIAL	70	44	358
PACLITAXEL	65	55	258
CARBOPLATIN + ETOPOSIDE	63	49	212
MITOMYCIN	100	93	169
FLUOROURACIL + MITOMYCIN + RT	110	107	156
MVAC	58	53	128
Other (98 regimens, including 3 other TRIAL regimen and 43 unrecognised)	577	525	1,519



Urology (Kidney)

All submitting trusts aggregated





Urology (Kidney)

All submitting trusts aggregated


Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
PAZOPANIB	1,010	702	4,741
SUNITINIB	852	527	3,113
AXITINIB	427	323	1,827
EVEROLIMUS	270	199	1,013
TRIAL	92	49	597
GEMCARBO	116	98	415
DENOSUMAB	67	54	279
CISPLATIN + GEMCITABINE	75	59	224
TEMSIROLIMUS	22	20	201
SORCE TRIAL	39	2	198
Other (131 regimens, including 8 other TRIAL regimen and 54 unrecognised)	366	261	1,168



Urology (Prostate)

### All submitting trusts aggregated





Urology (Prostate)

All submitting trusts aggregated

Data received for January 2014 - December 2014. Patients aged 16 and over

Regimen	Total Patients	First Cycles	Total Cycles
ABIRATERONE	2,995	1,783	16,248
DOCETAXEL	1,920	1,542	8,835
ENZALUTAMIDE	1,041	898	3,426
CABAZITAXEL	551	433	2,434
STAMPEDE TRIAL	130	42	1,072
TRIAL	199	117	882
MITOXANTRONE	53	40	205
CARBOPLATIN + ETOPOSIDE	60	53	167
DENOSUMAB	24	15	103
SAPROCAN TRIAL	20	19	82
Other (244 regimens, including 8 other TRIAL regimen and 133 unrecognised)	1,020	870	2,379